Category Archives: Genetics

Experiences with offering pro bono medical genetics services in the West Indies: Benefits to patients, physicians, and the community – DocWire News

This article was originally published here

Am J Med Genet C Semin Med Genet. 2020 Dec 4. doi: 10.1002/ajmg.c.31871. Online ahead of print.

ABSTRACT

We describe our experiences with organizing pro bono medical genetics and neurology outreach programs on several different resource-limited islands in the West Indies. Due to geographic isolation, small population sizes, and socioeconomic disparities, most Caribbean islands lack medical services for managing, diagnosing, and counseling individuals with genetic disorders. From 2015 to 2019, we organized 2-3 clinics per year on various islands in the Caribbean. We also organized a week-long clinic to provide evaluations for children suspected of having autism spectrum disorder. Consultations for over 100 different individuals with suspected genetic disorders were performed in clinics or during home visits following referral by locally registered physicians. When possible, follow-up visits were attempted. When available and appropriate, clinical samples were shipped to collaborating laboratories for molecular analysis. Laboratory tests included karyotyping, cytogenomic microarray analysis, exome sequencing, triplet repeat expansion testing, blood amino acid level determination, biochemical assaying, and metabolomic profiling. We believe that significant contributions to healthcare by genetics professionals can be made even if availability is limited. Visiting geneticists may help by providing continuing medical education seminars. Clinical teaching rounds help to inform local physicians regarding the management of genetic disorders with the aim of generating awareness of genetic conditions. Even when only periodically available, a visiting geneticist may benefit affected individuals, their families, their local physicians, and the community at large.

PMID:33274544 | DOI:10.1002/ajmg.c.31871

See the article here:
Experiences with offering pro bono medical genetics services in the West Indies: Benefits to patients, physicians, and the community - DocWire News

Viewpoint: Genetics and AI have launched an agricultural revolution. But ‘blind techno-optimism’ could have harmful consequences – Genetic Literacy…

Depending on who you listen to, artificial intelligence may either free us from monotonous labour and unleash huge productivity gains, or create a dystopia of mass unemployment and automated oppression. In the case of farming, some researchers, business people and politiciansthink the effects of AI and other advanced technologies are so great they are spurring a fourth agricultural revolution.

Given the potentially transformative effects of upcoming technology on farming positive and negative its vital that wepause andreflect before the revolution takes hold. Itmust work for everyone, whether it be farmers (regardless of their size or enterprise), landowners, farm workers, rural communities or the wider public. Yet, in arecently published studyled by the researcher Hannah Barrett, we found that policymakers and the media and policymakers are framing the fourth agricultural revolution as overwhelmingly positive, without giving much focus to the potential negative consequences.

The first agricultural revolution occurred when humans started farming around 12,000 years ago. The second was the reorganization of farmland from the 17th century onwards that followed the end of feudalism in Europe. And the third (also known as the green revolution) was the introduction of chemical fertilizers, pesticides and new high-yield crop breeds alongside heavy machinery in the 1950s and 1960s.

The fourth agricultural revolution, much like thefourth industrial revolution, refers to the anticipated changes from new technologies, particularly theuse of AIto make smarter planning decisions and power autonomous robots. Such intelligent machines could be used for growing and picking crops, weeding, milking livestock and distributing agrochemicalsvia drone. Other farming-specific technologies include new types ofgene editingto develop higher yielding, disease-resistant crops;vertical farms; andsynthetic lab-grown meat.

These technologies are attractinghuge amountsof funding and investmentin the quest to boost food production while minimizing further environmental degradation. This might, in part, be related to positive media coverage.Our researchfound that UK coverage of new farming technologies tends to be optimistic, portraying them as key to solving farming challenges.

However, many previous agricultural technologies were also greeted with similar enthusiasm before leading to controversy later on, such as with the firstgenetically modified cropsand chemicals such as the now-bannedpesticide DDT. Given wider controversies surrounding emergent technologies likenanotechnologyanddriverless cars, unchecked or blind techno-optimism is unwise.

We mustnt assume that all of these new farming technologies will be adopted without overcoming certain barriers. Precedent tells us that benefits are unlikely to be spread evenly across society and that some people will lose out. We need to understand who might lose andwhat we can doabout it, and ask wider questions such as whether new technologies will actually deliver as promised.

Robotic milking of cows provides a good example. In our research, a farmer told us that using robots had improved his work-life balance and allowed a disabled farm worker to avoid dextrous tasks on the farm. But they had also created a different kind of stress due to the resulting information overload and the perception that the farmer needed to be monitoring data 24/7.

TheNational Farmers Union(NFU) argues that new technologiescould attractyounger, more technically skilled entrants to an ageing workforce. Such breakthroughs could enable a wider range of people to engage in farming by eliminating the back-breaking stereotypes through greater use of machinery.

But existing farm workers at risk of being replaced by a machine or whose skills are unsuited to a new style of farming will inevitably be less excited by the prospect of change. And theymay not enjoybeing forced to spend less time working outside, becoming increasingly reliant on machines instead of their own knowledge.

There are also potentialpower inequalitiesin this new revolution. Our research found that some farmers were optimistic about a high-tech future. But others wondered whether those with less capital, poor broadband availability and IT skills, and access to advice on how to use the technology would be able to benefit.

History suggests technology companies and larger farm businesses are often the winners of this kind of change, and benefits dont always trickle down to smaller family farms. In the context of the fourth agricultural revolution, this could mean farmers not owning or being able to fully accessthe datagathered on their farms by new technologies. Or reliance on companies to maintain increasingly important and complex equipment.

The controversy surrounding GM crops (which are created by inserting DNA from other organisms) provides a frank reminder that there is no guarantee that new technologies will be embraced by the public. A similar backlash could occur if the public perceive gene editing (which instead involves making small, controlled changes to a living organisms DNA) as tantamount to GM. Proponents ofwearable technology for livestockclaim they improve welfare, but the public might see the use of such devices as treatinganimals like machines.

Instead of blind optimism, we need to identify where benefits and disadvantages of new agricultural technology will occur and for whom. This process must include a wide range of people to help create society-wideresponsible visionsfor the future of farming.

The NFUhas said the fourth agricultural revolution is exciting as well as a bit scary but then the two often go together. It is time to discuss the scary aspects with the same vigor as the exciting part.

David Rose is the Elizabeth Creak Associate Professor of Agricultural Innovation and Extension at the University of Reading. Find David on Twitter @d_christianrose

Charlotte-Anne Chivers is a research assistant at the Countryside and Community Research Institute at the University of Gloucestershire, working primarily on the EU-funded SPRINT and SoilCare projects. Find Charlotte-Anne on Twitter @cachivers

A version of this article was originally posted at the Conversation and has been reposted here with permission. The Conversation can be found on Twitter @ConversationUS

See the rest here:
Viewpoint: Genetics and AI have launched an agricultural revolution. But 'blind techno-optimism' could have harmful consequences - Genetic Literacy...

New Generation Genetics Bulls Lead the Way Following the Genetic Evaluations in December – Hoard’s Dairyman

The information below has been supplied by dairy marketers and other industry organizations. It has not been edited, verified or endorsed by Hoards Dairyman.

Following the release of the December 2020 genetic evaluations, bulls from New Generation Genetics proven and genomic bulls ranked at or near the top for Milk, Components, Type, Udder Composite, Mobility, Fertility, DPR, Productive Life, NM$, PPR, & Profitability.

BMG Lust GET LUCKY held his spot as the breeds #1 proven bull for milk and protein pounds at a remarkable +2578M, +57P, and +56F to go along with it. He remains in the top 10 Proven bulls ranking #3 at +146PPR.

Hilltop Acres B DAREDEVIL added nearly 100 daughters to his proof and continues his reign as the #1 proven type bull in the Brown Swiss breed at +0.80 and an exceptional udder composite of +1.22.

Jo-Lane Dario HAMPTON, the #2 proven PPR bull at 149, continues to create profitable cows through his outstanding health traits and daughter fertility with +5.8PL, +2.66SCS and +1.7DPR. He also ranks #2 for Net Merit and #2 for productive life.

Switzer Tals Pyssli DARIO, the sire of HAMPTON, claimed his title as the top proven PPR, Net Merit and productive life bull in the breed at +161PPR, +480NM$ and +6.1PL. He also provides great production at +968M and +40P.

La Rainbow Sweet SALSA ETV *TM ranks #2 for G-type at +1.0. He offers type without sacrificing production at +1330M +44F, +41P.

La Rainbow Sweet SPARK *NP ETV *TM, the polled bull hailing from the same maternal line as SALSA, is the top polled genomic bull for type and udder composite at +0.8T, +1.14UDC, +0.6DPR, and +732M.

Triangle Acres Carter JUKE is ranked #4 for G-type at +0.80. He also provides +1.22UDC, +292M, +1.0DPR +4.2PL. JUKE is now available in preferred sexed.

We also offer the CHAMPIONS COLLECTION elite sire lineup including 54BS600 WINRITE, 54BS602 FIRST CHOICE, 54BS539 RICHARD, 54BS581 RASTA, 54BS568 FAST & FURIOUS, and 54BS548 WINNING FORMULA.

New Generation Genetics offers the most comprehensive Brown Swiss Sires portfolio in the U.S. For further information call 920-568-0554, visit our Facebook page http://www.facebook.com/newgenerationgenetics, email info@brownswiss.com or visit http://www.brownswiss.com.

View post:
New Generation Genetics Bulls Lead the Way Following the Genetic Evaluations in December - Hoard's Dairyman

Teach Me in 10 Why COVID-19 Genetics Research May Be Biased With Dr Thomas Stoeger – Technology Networks

When applying genetics to the study of COVID-19, scientists are learning a lot. Our DNA codes for proteins, some of which are required for SARS-CoV-2 to interact with and infect a host cell, others that are implicated in the downstream effects of viral infection, such as inflammatory responses. But how do scientists choose which genes to study?A new study by Dr Thomas Stoeger, a postdoc at North Western University, suggests there is a historical bias involved; scientists are studying human genes that have already been heavily investigated, independent of COVID-19.

In this installment of Teach Me in 10, Stoeger expands on the key points of this study and the implications of bias in scientific research.

Full research publication: Meta-Research: COVID-19 research risks ignoring important host genes due to pre-established research patterns.

For more Teach Me in 10 videos, check out our hub page.

Are you a Facebook user? Like the Teach Me in 10 Facebook page to engage and network with the video audience.

Go here to read the rest:
Teach Me in 10 Why COVID-19 Genetics Research May Be Biased With Dr Thomas Stoeger - Technology Networks

Rare genetic differences play vital role in blood pressure – British Heart Foundation

New genetic differences have been discovered to play a vital role in regulating blood pressure, according to research part funded by us and published in Nature Genetics.

Researchers based at the University of Cambridge and round the world studied the genetic make-up of 1.3 million people with diverse ancestries. They found 106 new regions of DNA and 87 new rare genetic variations associated with blood pressure.

The rare genetic variants had an eight times greater effect on blood pressure compared to more common variants. Thirty-two of the rare variants were located within newly identified sections of DNA linked to blood pressure, and 55 were located within genes already known to be associated with its regulation.

The importance of the work is illustrated by the finding that six of the genes identified in this study, four of which contain rare variants, are already drug targets for heart and circulatory conditions. This suggests that the other genes identified may also be good targets for developing new drugs.

The researchers therefore hope that these findings will lead to new ways to prevent and treat high blood pressure.

Professor Sir Nilesh Samani, our Medical Director, said:

This major study has revealed new underlying genetic factors which add to the blueprint of what dictates our blood pressure.

High blood pressure is a major risk factor for heart and circulatory diseases. These new discoveries should shed light on potential new ways to prevent and treat high blood pressure and ensure its in a healthy range, ultimately to reduce deadly heart attacks and strokes.

Read more about high blood pressure

Read the original post:
Rare genetic differences play vital role in blood pressure - British Heart Foundation

Researchers Sequence Genome of Tomato’s Wild Ancestor | Genetics – Sci-News.com

Scientists at Boyce Thompson Institute have produced a high-quality chromosome-scale genome sequence for the currant tomato Solanum pimpinellifolium, the wild progenitor of the modern cultivated tomato Solanum lycopersicum.

Solanum pimpinellifolium in Botanisk tidsskrift, 1872.

Tomato is the worlds leading vegetable crop with a total production of 182 million tons and a worth over US $60 billion in 2018.

Solanum pimpinellifolium carrying red, small, and round fruits is the wild progenitor of the cultivated tomato.

It was domesticated in South America to give rise to Solanum lycopersicum var. cerasiforme, which was later improved into the big-fruited tomato Solanum lycopersicum var. lycopersicum in Mesoamerica.

Although other groups had previously sequenced Solanum pimpinellifolium, the new reference genome is more complete and accurate, thanks in part to cutting-edge sequencing technologies that are able to read very long pieces of DNA, said co-lead author Dr. Zhangjun Fei, a researcher at Boyce Thompson Institute and Robert W. Holley Center for Agriculture and Health at the U.S. Department of Agricultures Agricultural Research Service.

Older sequencing technologies that read short pieces of DNA can identify mutations at the single-base level, said co-lead author Dr. Shan Wu, a postdoctoral scientist at Boyce Thompson Institute.

But they arent good at finding structural variants, like insertions, deletions, inversions or duplications of large chunks of DNA.

Many known traits of the tomato are caused by structural variants, so that is why we focused on them, Dr. Fei said.

Structural variants also are understudied because they are more difficult to identify.

The scientists compared their reference genome of Solanum pimpinellifolium to that of the cultivated tomato, called Heinz 1706, and found more than 92,000 structural genetic variants.

They then combed the tomato pan-genome, a database with the genomes of more than 725 cultivated and closely related wild tomatoes, and discovered structural variants related to many important traits.

For example, the modern cultivated tomato has some genomic deletions that reduce their levels of lycopene, a red pigment with nutritional value, and an insertion that reduces their sucrose content.

Identification of the additional genetic diversity captured in the Solanum pimpinellifolium genome provides breeders with opportunities to bring some of these important features back to store-bought tomatoes, said co-author Dr. Jim Giovannoni, a researcher at Boyce Thompson Institute and Robert W. Holley Center for Agriculture and Health at the U.S. Department of Agricultures Agricultural Research Service.

The authors found many other structural variants that could be of interest to plant breeders, including variants in numerous disease-resistance genes and in genes involved in fruit size, ripening, hormonal regulation, metabolism, and the development of flowers, seeds and leaves.

They also found structural variants associated with regulating the expression of genes involved in the biosynthesis of lipids in fruit skin, which could help improve the fruits post-harvest performance.

So much genetic diversity was lost during tomato domestication, Dr. Fei said.

These data could help bring some of that diversity back and result in tomatoes that taste better, are more nutritious and more resilient.

The results appear in the journal Nature Communications.

_____

X. Wang et al. 2020. Genome of Solanum pimpinellifolium provides insights into structural variants during tomato breeding. Nat Commun 11, 5817; doi: 10.1038/s41467-020-19682-0

This article is based on a press-release provided by Boyce Thompson Institute.

Go here to read the rest:
Researchers Sequence Genome of Tomato's Wild Ancestor | Genetics - Sci-News.com

Insights on Human Genetics Market 2020 to 2027: COVID-19 Impact Analysis, Drivers, Opportunity Analysis, Restraints, and Forecast – The Courier

A new report added by Research Dive offers insights and puts forth the impact of COVID-19 catastrophe on the global human genetics market. According to the report, the human genetics market is estimated to grow at a significant rate and generate robust revenue share by 2027 during the forecast period from 2020 to 2027.

The report provides brief summary and an in-depth information of the market by collecting data from industry experts and different sources prevalent in the market. The statistics presented in the report are extensive, reliable, and the outcome of an exhaustive analytical research. The report offers qualitative and quantitative trend analysis for the period of 2020-2027 to assist stakeholders to understand the overall market scenario. Comprehensive analysis of the key segments validates the types of products used in the industry and their applications.

MARKET SEGMENTATION

On the basis of type, the global human genetics market is segmented into:

Product Type Segmentation Prenatal Genetics Cytogenetics Molecular Genetics & Symptom Genetics

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/request-toc-and-sample/2137

On the basis of application, the global human genetics market is segmented into:

Cytogenetics Molecular Genetics Prenatal Genetics Symptom Genetics Research Center Industry Segmentation Forensic Laboratories Hospital

On the basis of region, the global human genetics market is segmented into:

North America U.S. Canada Mexico

Europe Germany UK France Spain Italy Rest of Europe

Asia-Pacific Japan China India Australia South Korea Rest of Asia-Pacific

LAMEA Brazil Argentina Saudi Arabia South Africa UAE Rest of LAMEA

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/2137

KEY COMPANIES COVERED

The research report summarizes and outlines several aspects of the key players operating in the global human genetics market such as company snapshot, business performance, product portfolio, recent developments & strategies, SWOT analysis, and many more. The key players listed are:

LGC Forensics Agilent Technologies QIAGEN N.V. Bode Technology Illumina Thermo Fisher Scientific Inc. Promega Corporation Orchid Cellmark Inc. NextOmics GE Healthcare Takara Bio Inc. Oxford Nanopore Pacific Biosciences

RECENT DEVELOPMENTS

The key players of the market are adopting several strategies to obtain a leading position in the global industry. For instance, in August 2020, Ancestry launched AncestryHealth, a product that features next-generation sequencing with an ability to screen the genes associated with blood disorders, breast cancer, colon cancer, and heart disease.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:support@researchdive.comLinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

See more here:
Insights on Human Genetics Market 2020 to 2027: COVID-19 Impact Analysis, Drivers, Opportunity Analysis, Restraints, and Forecast - The Courier

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX – BioSpace

MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the Company), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (Agreement).

Key Highlights

The Agreement will support GTG to expand its product offering and establish the mental health vertical by harnessing PREDICTIX, Taliazs pioneering decision-support and management platform to optimize patient treatment for mental health disorders. Starting in the field of depression, this genomic-based, Artificial Intelligence (AI) driven antidepressant selection technology, marks GTGs first foray into pharmacogenomics1.

George Muchnicki, GTGs Interim CEO stated: We are incredibly pleased to have partnered with Taliaz to bring their predictive and personalized mental health product to Australia and New Zealand. GTG are at the forefront of providing personalized and predictive products to empower patients to make informed decisions about their health. This distribution agreement is our first external product partnership and our first product within the mental health vertical. Mental health has remained at the forefront of media discussions and government initiatives within Australia, New Zealand and globally due to the ongoing social and economic impact and given the impact from the current global pandemic. We look forward to working closely with the Taliaz team to deliver their product into these markets at this critical time.

The execution of the Agreement is reliant on product regulatory clearance by the Therapeutic Goods Administration (TGA) in Australia and Food and Drug Administration (FDA) in the USA. Once cleared, GTG has committed to providing a minimum distribution of 8,000 tests over the initial three-year term with an associated minimum cost to GTG of $200,000 over the term, inclusive of licencing fees and a percentage based fee per test paid to Taliaz. Subject to the regulatory clearance process, GTG anticipates that PREDICTIX will be made available for sale and distribution in Australia and New Zealand in Q3 FY21 on GTGs existing Consumer Initiated Testing (CIT) platform, with end-customer pricing to be determined but anticipated to be in line with existing GTG product pricing.

PREDICTIX, developed by the private Israeli company, Taliaz, addresses the growing burden on society from depression, with 1 in 10 Americans2 and 1 in 8 Australians3 prescribed antidepressants per year. PREDICTIX enables a more accurate and rapid treatment plan for patients suffering from depression, reducingtreatment costs and the overall associated economic burden.

PREDICTIX is an algorithmic-based decision support tool that can improve todays antidepressant prescribing accuracy by 47%4. Combining DNA testing with AI, PREDICTIX empowers doctors to improve the assessment, treatment, and management of mental health disorders.

The PREDICTIX technology uses AI to analyse multiple data streams, including patients genomic, clinical history and demographic background, providing doctors with a personalized patient report. The report ranks the statistical efficacy and potential side effects of various antidepressant medication based on each patients genetic makeup andhealth record. This helps doctors optimize prescribing decisions for patients diagnosed with depressive disorder, where there is currently a long and painful trial and error period. PREDICTIX is CE-registered and commercially available in the UK, France and Israel, with the process underway for TGA approval.

Dekel Taliaz, CEO and Co-founder of Taliaz said, We are excited to partner with Genetic Technologies, world-leaders in the genetic risk assessment space. This new partnership will support rapid commercialization of PREDICTIX to help more depression sufferers in Australia, New Zealand and the USA, while adding a complementary and advanced mental health solution to GTGs growing suite of DNA tests.

The Agreement strengthens GTGs mission in creating a suite of tests to enable a holistic and predictive health assessment for patients, which can be adjusted to address the individual patient risks and needs. Establishing the first product within the mental health and pharmacogenetic space continues GTGs progress towards being able to offer a highly comprehensive suite of polygenic risk assessment tests via GTGs CIT platform and additional sales and marketing avenues as these are progressed.

This announcement was approved by the Board of Directors of Genetic Technologies Limited.

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Companys lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit http://www.gtglabs.com

About Taliaz

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE-registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence, PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. Starting in the field of depression, the PREDICTIX Genetics and PREDICTIX Digital products can improve todays prescribing accuracy by up to 47%4.

For more information, please visit predictix.ai.

The rest is here:
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX - BioSpace

Cranky camels make difficult dairy cows part two but technology and genetics are making some headway – Brooks Bulletin

Most camels and their cousins, alpacas and llamas, have a reputation for being somewhat irritable and belligerent; thats backed up with occasional bouts of spitting, biting and cantankerous behaviour. They have been domesticated for a few thousand years, but they still seem to have a lofty sense of dignity despite humans trying to break their spirit. The noble camel has endured being a beast of burden and even a racing animal. But becoming a dairy animal is a work in progress as patient folks who handle them have found out since they were first tamed. Humans have milked or tried to milk camels for thousands of years; the milk is particularly nutritious and a protein source in many middle east and African societies to this day. The fact that massive camel dairy operations have sprung up would indicate that camel milk is still popular within the middle easts urbanized community and has a growing interest in other parts of the world. Camel dairy operations have started up in the USA and Australia to supply new markets, but they are modest in size. The biggest hurdle is trying to turn the camel into an efficient dairy animal with ever-increasing regular milk production assisted by mechanical handling. Thats a description of the typical bovine dairy animal of today.From a dairy perspective, the camel cow is genetically 200 years behind the average bovine dairy cow. The camel is nowhere near as docile, cooperative, nor as remotely productive as a modern dairy cow. Thats the result of longtime intensive selection as none of the other milked species started out as happy, productive dairy animals. However, modern Western-style camel dairy operations are making progress through a genetic selection process, camel training and unique camel milking and handling equipment. Some of the large middle east camel dairy operations employ highly skilled professionals that guide production increases.Interestingly, a small tribal group in Northern Kenya who are highly dependent on camel milk has, through selection, created a higher milk yielding strain of camel, so it can be done. The one fast-track system to a better milking camel cow is through mass selection. In the middle east and Australia, they have access to literally hundreds of thousands of local camel cows, both wild and captive. That enables them through a process of elimination to find the one cow in a hundred that might make a good docile camel dairy cow for a commercial dairy operation. However, selection would seem to be the easy part; its the milking part where it gets more complicated. Unlike other milking species like goats, sheep and bovines, the camel does not easily let down its milk; it needs significant stimulation and then only produces at intervals. In traditional settings, the presence of a camel cows calf provides the stimulation, and a person then hand milks the cow. Considering the camels cranky nature, that alone would seem to be a dangerous and haphazard process, never mind the food safety and sanitation concerns. Clearly, that wont work in a commercial dairy operation where thousands of camels have to be milked twice a day. Hence the big sophisticated operators in the middle east have developed protocols and equipment that eliminates most calf stimulation. Still, they must be using some sort of method to keep milk production up on a regular and consistent basis. All of that would seem to be transferable to a potentially large operation in Alberta, but a reliable source of camels would be needed. The other part is the huge capital investment, one of the largest middle east dairies started with an investment of $20 million and now has over 500 employees. Granted, this large operator controls camel milk from production to processing to worldwide marketing. It must be profitable as these large operations continue to expand in the middle east. A substantial commercial camel dairy operation in North America would have some advantages. Firstly, there is seemingly a large local market to absorb camel milk. Secondly is camel feed. The big outfits in the middle east import large quantities of costly alfalfa hay and other feedstuffs from Australia and North America to provide consistent quality feed to produce a steady supply of milk. Mammals, in general, produce surplus milk only through excess fat and protein consumption. But feed and markets arent enough of an advantage its finding enough of those darned cranky camel cows to milk. More next time. Will Verboven is an ag opinion writer and ag policy advisor.

Like Loading...

Related

Read more:
Cranky camels make difficult dairy cows part two but technology and genetics are making some headway - Brooks Bulletin

Are Consumers Getting What They Think They Are with Genetic Testing? – YubaNet

Washington, D.C. November 30, 2020 Today Consumer Federation of America released a new report,Marketing Direct-to-Consumer Genetic Testing: Are Consumers Getting What They Think They Are?It examines the claims direct-to-consumer (DTC) genetic testing companies make for these services, the information they provide to consumers about them, the variance of results from one company to another, the up-selling that occurs, and the companies terms of service and privacy policies. With the holidays coming up and DTC genetic testing companies promoting their services as the perfect gift, we wanted to help educate consumers about the benefits, limitations, and risks of these tests, said report author, Susan Grant, CFAs Director of Consumer Protection and Privacy. Nick Roper, Administrative and Advocacy Associate at CFA, assisted her with the research.

Conducted with a grant from the Rose Foundation, the study focused on six companies: 23andMe, Ancestry, FamilyTreeDNA, HomeDNA, LivingDNA, and MyHeritage. In order to compare the results, CFAs Grant took the basic ancestry tests from each company. We found that theres much about these tests consumers may not realize, said Grant. They need to be better informed and better protected.

What the CFA Study Found

Consumers might be surprised to know that most DTC genetic tests are not reviewed by the government before theyre marketed to confirm the claims made for them, their accuracy, or their validity, said Grant. There is a lot of helpful information on DTC genetic testing companies websites about genetics and how their services work, but were concerned that not many consumers will delve into it and assume theyll get more detailed and conclusive results than they actually will.

Recommendations

On the basis of the study, CFA made these recommendations:

DTC genetic testing companies should refrain from making specific accuracy claims.

In conjunction with the report, CFA released tips for consumers,9 Questions and Answers about DTC Genetic Testing.The full report ishere. A shorter version of the report is availablehere.

More here:
Are Consumers Getting What They Think They Are with Genetic Testing? - YubaNet